Pattern analysis of drug-induced skin diseases

American Journal of Dermatopathology

Volumn 30, Issue 4, 2008, Pages 352-369

  Justiniano, Hildamari ^a   Berlingeri Ramos, Alma C ^a   Sánchez, Jorge L ^a  

^a UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

Drug eruptions; Histopathologic pattern

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BARBITURIC ACID DERIVATIVE; BEZAFIBRATE; CETIRIZINE; CHLORDIAZEPOXIDE; CLONIDINE; CORTICOSTEROID; DIURETIC AGENT; FLUOROURACIL; GRISEOFULVIN; HYDRALAZINE; HYDROXYZINE; INFLIXIMAB; LEVAMISOLE; LEVOCETIRIZINE; MEDROXYPROGESTERONE; METFORMIN; METRONIDAZOLE; MITOXANTRONE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PENICILLAMINE; PROCAINAMIDE; PSEUDOEPHEDRINE; SEDATIVE AGENT; UNINDEXED DRUG;

ACNE; ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; BULLOUS DERMATITIS; BULLOUS PEMPHIGOID; DISEASE COURSE; DRUG ERUPTION; DRUG INDUCED DISEASE; FIXED DRUG ERUPTION; GRANULOMATOSIS; HISTOPATHOLOGY; HUMAN; INFLAMMATORY DISEASE; LICHENOID ERUPTION; LUPUS LIKE SYNDROME; MEASLES LIKE RASH; PANNICULITIS; PEMPHIGOID; PEMPHIGUS; PHOTOALLERGY; PHOTODERMATOSIS; PHOTOTOXICITY; PIGMENTED PURPURIC DERMATOSIS; PITYRIASIS ROSEA; PRIORITY JOURNAL; PSEUDOLYMPHOMA; PSEUDOPORPHYRIA; PSORIASIS; PUSTULE; REVIEW; SCLERODERMA; SKIN DISEASE; SKIN FIBROSIS; SKIN INFLAMMATION; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; URTICARIA; VASCULITIS; WELLS SYNDROME; CHEMICALLY INDUCED DISORDER; PATHOLOGY;

DRUG ERUPTIONS; HUMANS; SKIN DISEASES;

EID: 51149123303     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: 10.1097/DAD.0b013e3181722ef4     Document Type: Review

References (240)

1. Caranasos GJ, May FE, Stewart RB, et al. Drug associated deaths of medical inpatients. Arch Intern Med. 1976;136:872-875.
2. Ackerman AB, Chongchitnant N, Sanchez J, et al. Histologic Diagnosis of Inflammatory Skin Diseases. An Algorithmic Method Based on Pattern Analysis. 2nd ed. Baltimore, MD: Williams and Wilkins; 1997.
3. Yung A, Goulden V. Pigmented purpuric dermatosis (capillaritis) induced by bezafibrate. J Am Acad Dermatol. 2005;53:168-169.
4. Díaz-Jara M, Tornero P, Barrio MD. Pigmented purpuric dermatosis due to pseudoephedrine. Contact Dermatitis. 2002;46:300-1.
5. Ratnam KV, Su WP, Peters MS. Purpura simplex (inflammatory purpura without vasculitis): a clinicopathologic study of 174 cases. J Am Acad Dermatol. 1991;25:642-647.
6. Adams BB, Gadenne AS. Glipizide-induced pigmented purpuric dermatosis. J Am Acad Dermatol. 1999;41:827-829.
7. Kwon SJ, Lee CW. Figurate purpuric eruptions on the trunk: acetaminophen-induced rashes. J Dermatol. 1998;25:756-758.
8. Nishioka K, Katayama I, Masuzawa M, et al. Drug-induced chronic pigmented purpura. J Dermatol. 1989;16:220-222.
9. Nishioka K, Sarashi C, Katayama I. Chronic pigmented purpura induced by chemical substances. Clin Exp Dermatol. 1980;5:213-218.
10. Voelter WW. Pigmented purpuric dermatosis-like reaction to topical fluorouracil. Arch Dermatol. 1983;119:875-876.
11. Stratakis CA, Chrousos GP. Capillaritis (purpura simplex) associated with use of aminoglutethimide in Cushing's syndrome. Am J Hosp Pharm. 1994;51:2589-2591.
12. Gupta G, Holmes SC, Spence E, et al. Capillaritis associated with interferon-alfa treatment of chronic hepatitis C infection. J Am Acad Dermatol. 2000;43:937-938.
13. Tsao H, Lerner LH. Pigmented purpuric eruption associated with injection medroxyprogesterone acetate. J Am Acad Dermatol. 2000;43: 308-310.
14. Abeck D, Gross GE, Kuwert C, et al. Acetaminophen-induced progressive pigmentary purpura (Schamberg's disease). J Am Acad Dermatol. 1992;27:123-4.
15. Schäfer T, Ring J. Epidemiology of urticaria. In: Burr ML, ed. Epidemiology of Clinical Allergy. MonogrAllergy. Basel, Switzerland: Karger; 1993;31:49-60.
16. Kozel MM, Mekkes JR, Bossuyt PM, et al. The effectiveness of a history-based diagnostic approach in chronic urticaria and angioedema. Arch Dermatol. 1998;134:1575-1580.
17. Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol. 2001; 137:765-770.
18. Nikas SN, Voulgari PV, Drosos AA. Urticaria and angioedema-like skin reactions in a patient treated with adalimumab. Clin Rheumatol. 2007;26: 787-788.
19. Tutar E, Ekici F, Nacar N, et al. Delayed maculopapular, urticarial rash due to infliximab in two children with systemic onset juvenile idiopathic arthritis. Rheumatology. 2004;43:674-675.
20. Chang YS, Kwon HS, Cho SH, et al. A case of urticaria induced by both hydroxyzine and cetirizine but not by levocetirizine. Allergy. 2007;62: 819-821.
21. Kranke B, Mayr-Kanhauser S. Urticarial reaction to the antihistamine levocetirizine dihydrochloride. Dermatology. 2005;210:246-247.
22. Atzori L, Pinna AL, Ferreli C, et al. Pityriasis rosea-like adverse reaction: review of the literature and experience of an Italian drug-surveillance center. Dermatol Online J. 2006;12:1.
23. Atzori L, Ferreli C, Pinna AL, et al. 'Pityriasis rosea-like' adverse reaction to lisinopril. J Eur Acad Dermatol Venereol. 2004;18:743-745.
24. Helfman RJ, Brickman M, Fahey J. Isotretinoin dermatitis simulating acute pityriasis rosea. Cutis. 1984;33:297-300.
25. Hanjani NM, Rencic A, Whitmore SE. Pityriasis rosea-like eruption due to bismuth. Cutis. 2006;77:166-168.
26. Wilkinson SM, Smith AG, Davis MJ, et al. Pityriasis rosea and discoid eczema: dose related reactions to treatment with gold. Ann Rheum Dis. 1992;51:881-884.
27. Maize JC, Tomecki KJ. Pityriasis rosea-like drug eruption secondary to metronidazole. Arch Dermatol. 1977;113:1457-1458.
28. Buckley C. Pityriasis rosea-like eruption in a patient receiving omeprazole. Br J Dermatol. 1996;135:660-661.
29. Gupta AK, Lynde CW, Lauzon GJ, et al. Cutaneous adverse effects associated with terbinafine therapy: 10 case reports and a review of the literature. Br J Dermatol. 1998;138:529-532.
30. Scheinfeld N. Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate. J Drugs Dermatol. 2006;5: 228-231.
31. Brazzelli V, Prestinari F, Roveda E, et al. Pityriasis rosea-like eruption during treatment with imatinib mesylate: description of 3 cases. J Am Acad Dermatol. 2005;53:S240-S243.
32. Sasmaz S, Karabiber H, Boran C, et al. Pityriasis rosea-like eruption due to pneumococcal vaccine in a child with nephrotic syndrome. J Dermatol. 2003;30:245-247.
33. De Keyser F, Naeyaert JM, Hindryckx P, et al. Immune-mediated pathology following hepatitis B vaccination: two cases of polyarteritis nodosa and one case of pityriasis rosea-like drug eruption. Clin Exp Rheumatol. 2000;18:81-85.
34. Honl BA, Keeling JH, Lewis CW, et al. A pityriasis rosea-like eruption secondary to bacillus Calmette-Guerin therapy for bladder cancer. Cutis. 1996;57:447-450.
35. Kaplan B, Grunwald MH, Halevy S. Pityriasis rosea-like eruption associated with BCG vaccination. Isr J Med Sci. 1989;25:570-572.
36. Witherspoon FG, Thibodaux DJ. Pityriasis-rosea-like eruption following smallpox vaccination. AMA Arch Derm. 1957;76:109-110.
37. Mavakar L. Pityriasis rosea occurring during acyclovir therapy. Indian J Dermatol Venereol Leprol. 2007;73:200-201.
38. Seelvag E. Clinical drug photosensitivity: a retrospective analysis of reports to the Norwegian Adverse Drug Reactions Committee from the years 1970-1994. Photodermatol Photoimmunol Photomed. 1997;13: 21-23.
39. Allen JE. Drug induced photosensitivity. Clin Pharm. 1993;12:580-587.
40. Moore DE. Drug-induced cutaneous photosensitivity: incidence, mechanism, prevention and management. Drug Saf. 2002;25:345-372.
41. Crowson AN, Magro CM. Recent advances in the pathology of cutaneous drug eruptions. Dermatol Clin. 1999;17:537-560.
42. Gonzalez E, Gonzalez S. Drug photosensitivity, idiopathic photodermatoses, and sunscreens. J Am Acad Dermatol. 1996;35:871-875.
43. Crowson AN, Brown TJ, Magro CM. Progress in the understanding of the pathology and pathogenesis of cutaneous drug eruptions. Am J Clin Dermatol. 2003;4:407-428.
44. Wolfe JT, Singh A, Lessin SR, et al. De novo development of psoriatic plaques in patients receiving interferon alfa for treatment of eryth-rodermic cutaneous T-cell lymphoma. J Am Acad Dermatol. 1995;32: 887-893.
45. Pirard D, Arco D, Debrouckere V, et al. Anti-tumor necrosis factor alpha-induced psoriasiform eruptions: three further cases and current overview. Dermatology. 2006;213:182-186.
46. Sfikakis PP, Iliopoulos A, Elezoglou A, et al. Psoriasis induced by antitumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum. 2005;52:2513-2518.
47. Tan B, Foley P. Guttate psoriasis following Ecstasy ingestion. Australas J Dermatol. 2004;45:167-169.
48. Koca R, Altinyazar HC, Yenidünya S, et al. Psoriasiform drug eruption associated with metformin hydrochloride: a case report. Dermatol Online J. 2003;9:11.
49. Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: The reactive metabolite syndromes. Lancet. 2000;356:1587-1591.
50. Zohdi-Mofid M, Horn TD. Acrosyringeal concentration of necrotic keratinocytes in erythema multiforme: a clue to drug etiology. Clinicopathologic review of 29 cases. J Cutan Pathol. 1997;24:235-240.
51. Akosa AB, Elhag AM. Toxic epidermal necrolysis. A study of the sweat glands. J Cutan Pathol. 1995;22:359-364.
52. Nagore E, Insa A, Sanmartín O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ("hand-foot") syndrome. Incidence recognition and management. Am J Clin Dermatol. 2000;1: 225-234.
53. Webster-Gandy JD, How C, Harrold K. Palmar-plantar erythrodyses-thesia (PPE): a literature review with commentary on experience in a cancer centre. Eur J Oncol Nurs. 2007;11:238-246.
54. Janusch M, Fischer M, Marsch WCh, et al. The hand-foot syndrome-a frequent secondary manifestation in antineoplastic chemotherapy. Eur J Dermatol. 2006;16:494-499.
55. Yang CH, Lin WC, Chuang CK, et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol. 2008;158:592-596.
56. Rosenbaum SE, Wu S, Newman MA, et al. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer. 2008;15[epub ahead of print].
57. Suwattee P, Chow S, Berg BC, et al. Sunitinib: a cause of bullous palmoplantar erythrodysesthesia, periungual erythema, and mucositis. Arch Dermatol. 2008;144:123-125.
58. Orchard DC, Varigos GA. Fixed drug eruption to tartrazine. Australas J Dermatol. 1997;38:212-214.
59. Ritter SE, Meffert J. A refractory fixed drug reaction to a dye used in an oral contraceptive. Cutis. 2004;74:243-244.
60. Vilaplana J, Romaguera C. Fixed drug eruption from sodium benzoate. Contact Dermatitis. 2003;49:290-291.
61. Sehgal VN, Srivastava G. Fixed drug eruption (FDE): changing scenario of incriminating drugs. Int J Dermatol. 2006;45:897-908.
62. Zanolli MD, McAlvany J, Krowchuk DP. Phenolphthalein-induced fixed drug eruption: a cutaneous complication of laxative use in a child. Pediatrics. 1993;91:1199-1201.
63. Alanko K, Kanerva L, Mohell-Talolahti B, et al. Nonpigmented fixed drug eruption from pseudoephedrine. J Am Acad Dermatol. 1996;35: 647-648.
64. Ozkaya-BayRazit E. Specific site involvement in fixed drug eruption. J Am Acad Dermatol. 2003;49:1003-1007.
65. Young PC, Montemarano AD, Lee N, et al. Hypersensitivity to paclitaxel manifested as a bullous fixed drug eruption. J Am Acad Dermatol. 1996; 34:313-314.
66. Sigal-Nahum M, Konqui A, Gaulier A, et al. Linear fixed drug eruption. Br J Dermatol. 1988;118:849-851.
67. Mahboob A, Haroon TS. Drugs causing fixed drug eruptions: a study of 450 cases. Int J Dermatol. 1998;37:833-838.
68. Hernandez-Salazar A, De Leon-Rosales S, Rangel-Frausto S, et al. Epidemiology of adverse cutaneous drug reactions. A prospective study in hospitalized patients. Arch Med Res. 2006;37:899-902.
69. Fiszenson-Albala F, Auzerie V, Mahe E, et al. A 6-month prospective survey of cutaneous drug reactions in a hospital setting. Br J Dermatol. 2003;149:1018-1022.
70. Carlson JA, Perlmutter A, Tobin E, et al. Adverse antibiotic-induced eruptions associated with Epstein-Barr virus infection and showing Kikuchi-Fujimoto disease-like histology. Am J Dermatopathol. 2006;28: 48-55.
71. Facchetti F, Vermi W, Mason D, et al. The plasmacytoid monocyte/ interferon producing cells. Virchows Arch. 2003;443:703-717.
72. Cameron HA, Ramsay LE. The lupus syndrome induced by hydralazine: a common complication with low dose treatment. Br Med J. 1984;289: 410-412.
73. Goebel C, Vogel C, Wulferink M, et al. Procainamide, a drug causing lupus, induces prostaglandin H synthase-2 and formation of T cell-sensitizing drug metabolites in mouse macrophages. Chem Res Toxicol. 1999;12:488-500.
74. Pavlidakey GP, Hashimoto K, Heller GL, et al. Chlorpromazine-induced lupuslike disease. Case report and review of the literature. J Am Acad Dermatol. 1985;13:109-115.
75. Balestrero S, Ciambellotti A, Parodi A, et al. Minocycline-induced lupus-like syndrome. Int J Dermatol. 2001;40:474-475.
76. Pelizza L, De Luca P, La Pesa M, et al. Drug-induced systemic lupus erythematosus after 7 years of treatment with carbamazepine. Acta Biomed Ateneo Parmense. 2006;77:17-19.
77. Rich MW. Drug-induced lupus. The list of culprits grows. Postgrad Med. 1996;100:299-302, 307-308.
78. Carroll DG, Cavanagh LE. Drug-induced lupus associated with synthetic conjugated estrogens. Ann Pharmacother. 2007;41:702-706.
79. Crowson AN, Magro CM. Diltiazem and subacute cutaneous lupus erythematosus-like lesions. N Engl J Med. 1995;333:1429.
80. Gubinelli E, Cocuroccia B, Girolomoni G. Subacute cutaneous lupus erythematosus induced by nifedipine. J Cutan Med Surg. 2003;7: 243-246.
81. Reed BR, Huff JC, Jones SK, et al. Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy. Ann Intern Med. 1985;103:49-51.
82. Roura M, Lopez-Gil F, Umbert P. Systemic lupus erythematosus exacerbated by piroxicam. Dermatologica. 1991;182:56-58.
83. Miyagawa S, Okuchi T, Shiomi Y, et al. Subacute cutaneous lupus erythematosus lesions precipitated by griseofulvin. J Am Acad Dermatol. 1989;21:343-346.
84. Cetkovska P, Pizinger K. Coexisting subacute and systemic lupus erythematosus after terbinafine administration: successful treatment with mycophenolate mofetil. Int J Dermatol. 2006;45:320-322.
85. Spillane AP, Xia Y, Sniezek PJ. Drug-induced lupus erythematosus in a patient treated with adalumimab. J Am Acad Dermatol. 2007;56:S114- S116.
86. Benucci M, Li Gobbi F, Fossi F, et al. Drug-induced lupus after treatment with infliximab in rheumatoid arthritis. J Clin Rheumatol. 2005;11: 47-49.
87. Kang MJ, Lee YH, Lee J. Etanercept-induced systemic lupus erythematosus in a patient with rheumatoid arthritis. J Korean Med Sci. 2006;21:946-949.
88. Stratigos AJ, Antoniou C, Stamathioudaki S, et al. Discoid lupus erythematosus-like eruption induced by infliximab. Clin Exp Dermatol. 2004;29:150-153.
89. David-Bajar KM, Bennion SD, DeSpain JD, et al. Clinical, histologic, and immunofluorescent distinctions between subacute cutaneous lupus erythematosus and discoid lupus erythematosus. J Invest Dermatol. 1992;99:251-257.
90. Valeski JE, Kumar V, Forman AB, et al. A characteristic cutaneous direct immunofluorescent pattern associated with Ro(SS-A) antibodies in subacute cutaneous lupus erythematosus. J Am Acad Dermatol. 1992;27: 194-198.
91. Magro CM, Crowson AN, Harrist TJ. The use of antibody to C5b-9 in the subclassification of lupus erythematosus. Br J Dermatol. 1996;134: 855-862.
92. Perez-Perez L, Cabanillas M, Pereiro Ferreiros MM, et al. Photosensitive lichenoid eruption and inhaled tiotropium bromide. Dermatology. 2007; 214:97-98.
93. Hague JS, Ilchyshyn A. Lichenoid photosensitive eruption due to capecitabine chemotherapy for metastatic breast cancer. Clin Exp Dermatol. 2007;32:102-103.
94. Dalmau J, Peramiquel L, Puig L, et al. Imatinib-associated lichenoid eruption: acitretin treatment allows maintained antineoplastic effect. Br J Dermatol. 2006;154:1213-1216.
95. Antiga E, Melani L, Cardinali C, et al. A case of lichenoid drug eruption associated with sildenafil citratus. J Dermatol. 2005;32:972-975.
96. Ackerman AB, Guo Y, Lasova R, et al. Differential Diagnosis in Dermatopathology II. 2nd ed. New York: Ardor Scribendi; 2001.
97. Albrecht J, Fine LA, Piette W. Drug-associated lymphoma and pseudolymphoma: recognition and management. Dermatol Clin. 2007; 25:233-244.
98. Crowson AN, Magro CM, Zahorchak R. A typical pigmentary purpura: a clinical, histopathologic, and genotypic study. Hum Pathol. 1999;30: 1004-1012.
99. D'Incan M, Souteyrand P, Bignon YJ, et al. Hydantoin-induced cutaneous pseudolymphoma with clinical, pathologic, and immunologic aspects of Sezary syndrome. Arch Dermatol. 1992;128:1371-1374.
100. Bolognia JL, Jorizzo JL, Rapini RP. Dermatology. Toronto, Canada: Elsevier Health Sciences; 2003.
101. Yanagi T, Sawamura D, Shimizu H. Follicular mucinosis associated with imatinib. Br J Dermatol. 2004;151:1272-1288.
102. Perez-Ferriols A, Martinez-Menchon T, Fortea JM. Follicular mucinosis secondary to captopril-induced photoallergy. Actas Dermosifiliogr [Spanish]. 2005;96:167-170.
103. Horn TD, Burke PJ, Karp JE, et al. Intravenous administration of recombinant human granulocyte-macrophage colony-stimulating factor causes a cutaneous eruption. Arch Dermatol. 1991;127:49-52.
104. Valks R, Vargas E, Munoz E, et al. Dermal infiltrate of enlarged macrophages in patients receiving chemotherapy. J Cutan Pathol. 1998; 25:259-264.
105. Scott GA. Report of three cases of cutaneous reactions to granulocyte macrophage-colony-stimulating factor and a review of the literature. Am J Dermatopathol. 1995;17:107-114.
106. Tomita Y, Shimizu T, Shimizu H. Granulocyte colony-stimulating factor (G-CSF) induced disseminated erythema with CD68 positive histiocytes. Acta Derm Venereol. 2001;81:436-437.
107. Alvarez-Ruiz S, Penas PF, Fernandez-Herrera J, et al. Maculopapular eruption with enlarged macrophages in eight patients receiving G-CSF or GM-CSF. J Eur Acad Dermatol Venereol. 2004;18:310-313.
108. Ferran M, Gallardo F, Salar A, et al. Granulomatous dermatitis with enlarged histiocytes: a characteristic pattern of granulocyte colony-stimulating factor. Report of two cases and review of the literature. Dermatology. 2006;212:188-193.
109. Magro CM, Crowson AN, Schapiro BL. The interstitial granulomatous drug reaction: a distinctive clinical and pathological entity. J Cutan Pathol. 1998;25:72-78.
110. Perrin C, Lacour JP, Castanet J, et al. Interstitial granulomatous drug reaction with a histological pattern of interstitial granulomatous dermatitis. Am J Dermatopathol. 2001;23:295-298.
111. Lim AC, Hart K, Murrell D. A granuloma annulare-like eruption associated with the use of amlodipine. Australas J Dermatol. 2002;43:24-27.
112. Deng A, Harvey V, Sina B, et al. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors. Arch Dermatol. 2006;142:198-202.
113. Fujita Y, Shimizu T, Shimizu H. A case of interstitial granulomatous drug reaction due to sennoside. Br J Dermatol. 2004;150:1035-1037.
114. Lee MW, Choi JH, Sung KJ, et al. Interstitial and granulomatous drug reaction presenting as erythema nodosum-like lesions. Acta Derm Venereol. 2002;82:473-474.
115. Lee HW, Yun WJ, Lee MW, et al. Interstitial granulomatous drug reaction caused by Chinese herbal medication. J Am Acad Dermatol. 2005;52: 712-713.
116. Sweet RD. An acute neutrophilic dermatosis. Br J Dermatol. 1964;76: 349-356.
117. Walker DC, Cohen PR. Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet's syndrome. J Am Acad Dermatol. 1996;34:918-923.
118. Saez M, Garcia-Bustinduy M, Noda A, et al. Drug-induced Sweet's syndrome. J Eur Acad Dermatol Venereol. 2004;18:233.
119. Kuechle MK, Stegemeir E, Maynard B, et al. Drug-induced linear IgA bullous dermatosis: report of six cases and review of the literature. J Am Acad Dermatol. 1994;30:187-192.
120. Wiadrowski TP, Reid CM. Drug-induced linear IgA bullous disease following antibiotics. Australas J Dermatol. 2001;42:196-199.
121. Waldman MA, Black DR, Callen JP. Vancomycin-induced linear IgA bullous disease presenting as toxic epidermal necrolysis. Clin Exp Dermatol. 2004;29:633-636.
122. Armstrong AW, Fazeli A, Yeh SW, et al. Vancomycin-induced linear IgA disease manifesting as bullous erythema multiforme. J Cutan Pathol. 2004;31:393-397.
123. Solky BA, Pincus L, Horan RF. Vancomycin-induced linear IgA bullous dermatosis: morphology is a key to diagnosis. Cutis. 2004;73:65-67.
124. Onodera H, Mihm MC Jr, Yoshida A, et al. Drug-induced linear IgA bullous dermatosis. J Dermatol. 2005;32:759-764.
125. Primka EJ III, Liranzo MO, Bergfeld WF, et al. Amiodarone-induced linear IgA disease. J Am Acad Dermatol. 1994;31:809-811.
126. Plunkett RW, Chiarello SE, Beutner EH. Linear IgA bullous dermatosis in one of two piroxicam-induced eruptions: a distinct direct immuno-fluorescence trend revealed by the literature. J Am Acad Dermatol. 2001; 45:691-696.
127. Yawalkar N, Reimers A, Hari Y, et al. Drug-induced linear IgA bullous dermatosis associated with ceftriaxone- and metronidazole-specific T cells. Dermatology. 1999;199:25-30.
128. Leonard JN, Haffenden GP, Ring NP, et al. Linear IgA disease in adults. Br J Dermatol. 1982;107:301-316.
129. Neughebauer BI, Negron G, Pelton S, et al. Bullous skin disease: an unusual allergic reaction to vancomycin. Am J Med Sci. 2002;323: 273-278.
130. Brenner S, Bialy-Golan A, Ruocco V. Drug-induced pemphigus. Clin Dermatol. 1998;16:393-397.
131. Mutasim DF, Pelc NJ, Anhalt GJ. Drug-induced pemphigus. Dermatol Clin. 1993;11:463-471.
132. Wolf R, Ruocco V. Gaining more insight into the pathomechanisms of thiol-induced acantholysis. Med Hypotheses. 1997;48:107-110.
133. Lin R, Ladd DJ Jr, Powell DJ, et al. Localized pemphigus foliaceus induced by topical imiquimod treatment. Arch Dermatol. 2004;140:889-890.
134. Campagne G, Roca M, Martinez A. Successful treatment of a high-grade intraepithelial neoplasia with imiquimod, with vulvar pemphigus as a side effect. Eur J Obstet Gynecol Reprod Biol. 2003;109:224-227.
135. Mashiah J, Brenner S. Possible mechanisms in the induction of pemphigus foliaceus by topical imiquimod treatment. Arch Dermatol. 2005;141:908-909.
136. Landau M, Brenner S. Histopathologic findings in drug-induced pemphigus. Am J Dermatopathol. 1997;19:411-414.
137. Brenner S, Bialy-Golan A, Anhalt GJ. Recognition of pemphigus antigens in drug-induced pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol. 1997;36:919-923.
138. Cohen LM, Skopicki OK, Harrist TJ. Noninfectious vesiculobullous and vesiculopustular disease. In: Elder D, Elenitsas R, Jaworsky C, et al, eds. Lever's Histopathology of the Skin. 8th ed. Philadelphia, PA: Lippincott-Raven; 1997:209-252.
139. Korman NJ, Eyre RW, Zone J, et al. Drug-induced pemphigus: autoantibodies directed against the pemphigus antigen complexes are present in penicillamine and captopril-induced pemphigus. J Invest Dermatol. 1991;96:273-276.
140. Bastuji-Garin S, Joly P, Picard-Dahan C, et al. Drugs associated with bullous pemphigoid. A case-control study. Arch Dermatol. 1996;132: 272-276.
141. Mehravaran M, Gyulai R, Husz S, et al. Drug-induced erythema multiforme-like bullous pemphigoid. Acta Derm Venereol. 1999;79:233.
142. Vassileva S. Drug-induced pemphigoid: bullous and cicatricial. Clin Dermatol. 1998;16:379-387.
143. Lee JJ, Downham TF II. Furosemide-induced bullous pemphigoid: case report and review of literature. J Drugs Dermatol. 2006;5:562-564.
144. Czechowicz RT, Reid CM, Warren LJ, et al. Bullous pemphigoid induced by cephalexin. Australas J Dermatol. 2001;42:132-135.
145. Perry A, Sparling JD, Pennington M. Bullous pemphigoid following therapy with an oral beta-blocker. J Drugs Dermatol. 2005;4:746-748.
146. Mallet L, Cooper JW, Thomas J. Bullous pemphigoid associated with captopril. DICP. 1989;23:63.
147. Marti-Huguet T, Quintana M, Cabiro I. Cicatricial pemphigoid associated with D-penicillamine treatment. Arch Ophthalmol. 1989;107:1115.
148. Joost TV, Crone RA, Overdijk AD. Ocular cicatricial pemphigoid associated with practolol therapy. Br J Dermatol. 1976;94:447-450.
149. Van Joost T, Faber WR, Manuel HR. Drug-induced anogenital cicatricial pemphigoid. Br J Dermatol. 1980;102:715-718.
150. Vassileva S. Drug-induced pemphigoid: bullous and cicatricial. Clin Dermatol. 1998;16:379-387.
151. Poh-Fitzpatrick MB. Porphyria, pseudoporphyria, pseudopseudoporphyria...? Arch Dermatol. 1986;122:403-404.
152. Meggitt SJ, Farr PM. Pseudoporphyria and propionic acid non-steroidal anti-inflammatory drugs. Br J Dermatol. 1999;141:591-592.
153. O'Donoghue NB, Higgins EM. Case 1: naproxen-induced pseudoporphyria. Clin Exp Dermatol. 2002;27:339-340.
154. Antony F, Layton AM. Nabumetone-associated pseudoporphyria. Br J Dermatol. 2000;142:1067-1069.
155. Ingrish G, Rietschel RL. Oxaprozin-induced pseudoporphyria. Arch Dermatol. 1996;132:1519-1520.
156. Markus R, Reddick ME, Rubenstein MC. Rofecoxib-induced pseudoporphyria. J Am Acad Dermatol. 2004;50:647-648.
157. Epstein JH, Seibert JS. Porphyria-like cutaneous changes induced by tetracycline hydrochloride photosensitization. Arch Dermatol. 1976;112: 661-666.
158. Bilsland D, Douglas WS. Sunbed pseudoporphyria induced by nalidixic acid. Br J Dermatol. 1990;123:547.
159. Phung TL, Pipkin CA, Tahan SR, et al. Beta-lactam antibiotic-induced pseudoporphyria. J Am Acad Dermatol. 2004;51:S80-S82.
160. Tolland JP, McKeown PP, Corbett JR. Voriconazole-induced pseudo-porphyria. Photodermatol Photoimmunol Photomed. 2007;23:29-31.
161. Breier F, Feldmann R, Pelzl M, et al. Pseudoporphyria cutanea tarda induced by furosemide in a patient undergoing peritoneal dialysis. Dermatology. 1998;197:271-273.
162. Leitao EA, Person JR. Bumetanide-induced pseudoporphyria. J Am Acad Dermatol. 1990;23:129-130.
163. Motley RJ. Pseudoporphyria due to dyazide in a patient with vitiligo. BMJ. 1990;300:1468.
164. Baker EJ, Reed KD, Dixon SL. Chlorthalidone-induced pseudoporphy-ria: clinical and microscopic findings of a case. J Am Acad Dermatol. 1989;21:1026-1029.
165. Parodi A, Guarrera M, Rebora A. Amiodarone-induced pseudoporphyria. Photodermatology. 1988;5:146-147.
166. Laidman PJ, Gebauer K, Trotter J. 5-Fluorouracil-induced pseudopor-phyria. Aust N Z J Med. 1992;22:385.
167. Hivnor C, Nosauri C, James W, et al. Cyclosporine-induced pseudoporphyria. Arch Dermatol. 2003;139:1373-1374.
168. Lim CK, Rideout JM, Peters TJ. Pseudoporphyria associated with consumption of brewers' yeast. Br Med J (Clin Res Ed). 1984;288:1640-1642.
169. Riordan CA, Anstey A, Wojnarowska F. Isotretinoin-associated pseudoporphyria. Clin Exp Dermatol. 1993;18:69-71.
170. McDonagh AJ, Harrington CI. Pseudoporphyria complicating etretinate therapy. Clin Exp Dermatol. 1989;14:437-438.
171. Borroni G, Brazzelli V, Baldini F, et al. Flutamide-induced pseudoporphyria. Br J Dermatol. 1998;138:711-712.
172. Judd L. Pseudoporphyria due to cola. Int J Dermatol. 1991;30:674-675.
173. Silver EA, Silver AH, Silver DS, et al. Pseudoporphyria induced by oral contraceptive pills. Arch Dermatol. 2003;139:227-228.
174. Maynard B, Peters MS. Histologic and immunofluorescence study of cutaneous porphyrias. J Cutan Pathol. 1992;19:40-47.
175. Beylot C, Doutre MS, Beylot-Barry M. Acute generalized exanthem-atous pustulosis. Semin Cutan Med Surg. 1996;15:244-249.
176. Lin JH, Sheu HM, Lee JY. Acute generalized exanthematous pustulosis with erythema multiforme-like lesions. Eur J Dermatol. 2002;12: 475-478.
177. Mengesha Y, Bennett M. Pustular skin disorders: diagnosis and treatment. Am J Clin Dermatol. 2002;3:389-400.
178. Sidoroff A, Halevy S, Bavinck JN, et al. Acute generalized exanthematous pustulosis (AGEP) - a clinical reaction pattern. J Cutan Pathol. 2001;28:113-119.
179. Ofuji S, Yamamoto O. Acute generalized exanthematous pustulosis associated with a human parvovirus B19 infection. J Dermatol. 2007;34: 121-123.
180. Hausermann P, Scherer K, Weber M, et al. Ciprofloxacin-induced acute generalized exanthematous pustulosis mimicking bullous drug eruption confirmed by a positive patch test. Dermatology. 2005;211:277-280.
181. Beltraminelli HS, Lerch M, Arnold A, et al. Acute generalized exanthematous pustulosis induced by the antifungal terbinafine: case report and review of the literature. Br J Dermatol. 2005;152:780-783.
182. Heinemann C, Wiesend CL, Hipler C, et al. Acute generalized exanthematous pustulosis (AGEP) after oral use of amphotericin B. J Am Acad Dermatol. 2007;57:S61-S63.
183. Demitsu T, Kosuge A, Yamada T, et al. Generalized exanthematous pustulosis induced by dexamethasone injection. Dermatology. 1996;193: 56-58.
184. Yesudian PD, Penny M, Azurdia RM, et al. Ibuprofen-induced acute generalized exanthematous pustulosis. Int J Dermatol. 2004;43:208-210.
185. Wohl Y, Goldberg I, Sharazi I, et al. A case of paracetamol-induced acute generalized exanthematous pustulosis in a pregnant woman localized in the neck region. Skinmed. 2004;3:47-49.
186. Byerly FL, Nelson KC, Granko RP, et al. Valdecoxib-associated acute generalized exanthematous pustulosis. Burns. 2005;31:383-387.
187. Weedon D. Skin Pathology. London: Churchill Livingstone; 2002.
188. Carlson JA. Ng BT, Chen KR. Cutaneous vasculitis update: diagnostic criteria, classification, epidemiology, etiology, pathogenesis, evaluation and prognosis. Am J Dermatopathol. 2005;27:504-528.
189. Bahrami S, Malone JC, Webb KG, et al. Tissue eosinophilia as an indicator of drug-induced cutaneous small-vessel vasculitis. Arch Dermatol. 2006;142:155-161.
190. Lee HH, Song IH, Friedrich M, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol. 2007;156:486-491.
191. García-Porrúa C, González-Gay MA, López-Lázaro L. Drug associated cutaneous vasculitis in adults in northwestern Spain. J Rheumatol. 1999; 26:1942-1944.
192. Cuellar ML. Drug-induced vasculitis. Curr Rheumatol Rep. 2002;4:55-59.
193. Ten Holder SM, Joy MS, Falk RJ. Cutaneous and systemic manifestations of drug-induced vasculitis. Ann Pharmacother. 2002;36:130-147.
194. Doyle MK, Cuellar ML. Drug-induced vasculitis. Expert Opin Drug Saf. 2003;2:401-409.
195. Kauffmann RH, Herrmann WA, Meijer CJ, et al. Circulating and tissue-bound immune complexes in allergic vasculitis: relationship between immunoglobulin class and clinical features. Clin Exp Immunol. 1980;41: 459-470.
196. García-Porrúa C, Llorca J, González-Louzao C, et al. Hypersensitivity vasculitis in adults: a benign disease usually limited to skin. Clin Exp Rheumatol. 2001;19:85-88.
197. Zeek PM, Smith CC, Weeter JC. Studies on periarteritis nodosa and hypersensitivity. Am J Pathol. 1948;24:889-917.
198. Mullick FG, McAllister HA, Wagner BM, et al. Drug related vasculitis: clinicopathologic correlations in 30 patients. Hum Pathol. 1979;10: 313-325.
199. Winkelmann RK, Ditto WB. Cutaneous and visceral syndromes of necrotizing or "allergic" angiitis: a study of 38 cases. Medicine. 1964; 43:59-89.
200. Chen KR, Su WP, Pittelkow MR, et al. Eosinophilic vasculitis in connective tissue disease. J Am Acad Dermatol. 1996;35:173-182.
201. Lee A, Thompson J. Drug-induced skin reactions. In: Lee A, ed. Adverse Drug Reactions. Chicago, IL: Pharmaceutical Press; 2006:125-156.
202. Kanzaki T. Acneiform eruption induced by lithium carbonate. J Dermatol. 1991;18:481-483.
203. Kunzle N, Venetz J-P, Pascual M, et al. Sirolimus-induced acneiform eruption. Dermatology. 2005;211:366-369.
204. Galimont-Collen AF, Vos LE, Lavrijsen AP, et al. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer. 2007;43: 845-851.
205. Warthan MM, Jumper CA, Smith JL. Acneiform eruption induced by Iressa (gefitinib) tablets used to treat non-small cell lung cancer. J Drugs Dermatol. 2004;3:569-570.
206. Journagan S, Obadiah J. An acneiform eruption due to erlotinib: prognostic implications and management. J Am Acad Dermatol. 2006; 54:358-360.
207. Molinari E, De Quatrebarbes J, Andre T, et al. Cetuximab-induced acne. Dermatology. 2005;211:330-333.
208. DeWitt CA, Siroy AE, Stone SP. Acneiform eruptions associated with epidermal growth factor receptor-targeted chemotherapy. J Am Acad Dermatol. 2007;56:500-505.
209. Elder DE, Elenitsas R, Johnson BL, et al. Lever's Histopathology of the Skin. 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004.
210. Ellis E, Scheinfeld N. Eosinophilic pustular folliculitis: a comprehensive review of treatment options. Am J Clin Dermatol. 2004;5:189-197.
211. Wolf R, Kuritzky J. Eosinophilic pustular folliculitis versus eosinophilic pustulosis. Dermatology. 1994;188:243.
212. Mizoguchi S, Setoyama M, Higashi Y, et al. Eosinophilic pustular folliculitis induced by carbamazepine. J Am Acad Dermatol. 1998;38:641-643.
213. Kimura K, Ezoe K, Yokozeki H, et al. A case of eosinophilic pustular folliculitis (Ofuji's disease) induced by patch and challenge tests with indeloxazine hydrochloride. J Dermatol. 1996;23:479-483.
214. Ooi CG, Walker P, Sidhu SK, et al. Allopurinol induced generalized eosinophilic pustular folliculitis. Australas J Dermatol. 2006;47:270-273.
215. Maejima H, Mukai H, Hikaru E. Eosinophilic pustular folliculitis induced by allopurinol and timepidium bromide. Acta Derm Venereol. 2002;82:316-317.
216. Laing ME, Laing TA, Mulligan NJ, et al. Eosinophilic pustular folliculitis induced by chemotherapy. J Am Acad Dermatol. 2006;54:729-730.
217. Mizukawa Y, Shiohara T. Eosinophilic pustular folliculitis induced after prolonged treatment with systemic corticosteroids in a patient with pustulosis palmoplantaris. Acta Derm Venereol. 1998;78:221-222.
218. Finch WF, Rodnan GP, Buckingham RB, et al. Bleomycin-induced scleroderma. J Rheumatol. 1980;7:651-659.
219. King SL, Lichtler AC, Rowe DW, et al. Bleomycin stimulates pro-alpha 1 (I) collagen promoter through transforming growth factor beta response element by intracellular and extracellular signaling. J Biol Chem. 1994; 269:13156-13161.
220. Battafarano DF, Zimmerman GC, Older SA, et al. Docetaxel (Taxotere) associated scleroderma-like changes of the lower extremities. Cancer. 1995;76:110-115.
221. Kupfer I, Balguerie X, Courville P, et al. Scleroderma-like cutaneous lesions induced by paclitaxel: a case study. J Am Acad Dermatol. 2003; 48:279-281.
222. Cleveland MG, Ajaikumar BS, Reganti R, et al. Cutaneous fibrosis induced by docetaxel. Cancer. 2000;88:1078-1081.
223. Itoh M, Yanaba K, Kobayashi T, et al. Taxane-induced scleroderma. Br J Dermatol. 2007;156:363-367.
224. Leshin B, Piette W, Caplan RM. Morphea after bromocriptine therapy. Int J Dermatol. 1989;28:177-179.
225. Kluger N, Girard C, Bessis D, et al. Methysergide-induced scleroderma-like changes of the legs. Br J Dermatol. 2005;153:224-225.
226. Mulligan-Kehoe MJ, Simons M. Current concepts in normal and defective angiogenesis: implications for systemic sclerosis. Curr Rheumatol Rep. 2007;9:173-179.
227. Silberstein SD. The pharmacology of ergotamine and dihydroergota-mine. Headache. 1997;37:S15-S25.
228. Ferzli GT, El-Tal AK, Kibbi AG, et al. Localized morphea: a rare adverse effect of valproic acid. Pediatr Neurol. 2003;29:253-255.
229. Biasi D, Caramaschi P, Carletto A, et al. Scleroderma and eosinophilic fasciitis in patients taking fosinopril. J Rheumatol. 1997;24:1242.
230. Requena L, Yus ES. Panniculitis. Part I. Mostly septal panniculitis. J Am Acad Dermatol. 2001;45:163-183.
231. Dellaripa PF, Wechsler ME, Roth ME, et al. Recurrent panniculitis in a man with asthma receiving treatment with leukotriene-modifying agents. Mayo Clin Proc. 2000;75:643-645.
232. de Fonclare AL, Khosrotehrani K, Aractingi S, et al. Erythema nodosum-like eruption as a manifestation of azathioprine hypersensitivity in patients with inflammatory bowel disease. Arch Dermatol. 2007;143: 744-748.
233. Assouline S, Laneuville P, Gambacorti-Passerini C. Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia. N Engl J Med. 2006;354:2623-2624.
234. Ugurel S, Lahaye T, Hildenbrand R, et al. Panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib. Br J Dermatol. 2003;149:678-679.
235. Jagdeo J, Campbell R, Long T, et al. Sweet's syndrome-like neutrophilic lobular panniculitis associated with all-trans-retinoic acid chemotherapy in a patient with acute promyelocytic leukemia. J Am Acad Dermatol. 2007;56:690-693.
236. Saint-Cyr I, Vezon G, Boisseau-Garsaud AM, et al. Panniculitis induced by MINE chemotherapy. Ann Dermatol Venereol. 2001;128:756-758.
237. Kismet E, Demirkaya E, Deveci S, et al. Panniculitis induced by a chemotherapy regimen consisting of topotecan and cyclophosphamide. Pediatr Blood Cancer. 2005;44:98-99.
238. Rodriguez E, Martinez JA, Torres M, et al. Lobular panniculitis associated with ciprofloxacin. BMJ. 1990;300:1468.
239. Fragasso G, Ciboddo G, Pagnotta P, et al. Septal panniculitis induced by atenolol-a case report. Angiology. 1998;49:499-502.
240. Popp AI, Armstrong D, Sepkowitz KA. Recurrent panniculitis in a patient receiving protease inhibitor therapy for human immunodeficiency virus infection. Clin Infect Dis. 1990;29:936-937.